Pediatric Cancer

Investigators assessed the frequency, fusion partners, and clinical course in pediatric patients with NTRK fusion–positive tumors.

Population-based study evaluated survival outcomes for patients with cancer diagnosed over a 41-year period.

Cancer incidence trends across 41 countries demonstrated sharp increases and decreases in certain cancer types over the last 15 years.

Pediatric medulloblastoma demonstrated a distinct methylation profile that could identify the disease and monitor treatment response.

As part of the Zero Childhood Cancer Program, high-risk pediatric tumors were characterized by whole-genome sequencing, RNA sequencing, and methylation profiling.

The FDA and EMA expressed the need for trial sponsors to coordinate their submissions of initial pediatric study plans and pediatric investigation plans for new oncology drugs.